Zohydro: Potent painkiller stirs debate over abuse vs. pain relief
When it comes to fighting heroin and the abuse of prescription medications, a potent new painkiller is stirring a debate that has one side fighting to protect the rights of chronic pain patients and the other side trying to fight the war on drugs.
At the center of the controversy is a new class of drugs that includes Zohydro, which was approved by the Food and Drug Administration late last year – against the recommendation by an internal advisory committee.
Since then, officials in many states have challenged the agency’s approval of the powerful new painkiller, including Vermont Gov. Peter Shumlin who just last week issued an emergency order that makes it more difficult for doctors to prescribe Zohydro.
Other state officials took similar actions because the drug can be highly addictive, not to mention crushed and snorted in a manner similar to heroin, making the war on drugs even harder.
This prompted Massachusetts Gov. Deval Patrick to ban Zohydro last week, which is the first time ever a drug has been banned in the state.
Then, at the end of last year, there were the 28 attorneys general from states across America who banned together urging the FDA to revoke its approval of Zohydro or require that the drug’s maker reformulate the medication to make it less likely to be abused.
Nevertheless, San Diego-based Zogenix, the maker of Zohydro, insists the drug is no more potent than any other hydrocodone medication. The company also says that it is taking steps to ensure that both doctors and patients are educated about the drug’s risks.